إعلان
إعلان

GTBP

GTBP logo

GT Biopharma Inc. Common Stock

0.69
USD
برعاية
+0.01
+0.74%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

0.68

-0.01
-0.88%

تقارير أرباح GTBP

النسبة الإيجابية المفاجئة

GTBP تفوق 11 من 18 آخر التقديرات.

61%

التقرير التالي

بيانات التقرير القادم
١٩ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.22
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
-72.15%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-86.75%

GT Biopharma Inc. Common Stock earnings per share and revenue

On ١٤ نوفمبر ٢٠٢٥, GTBP reported earnings of -0.79 USD per share (EPS) for Q3 25, missing the estimate of -0.38 USD, resulting in a -103.82% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -25.34% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 المحللين forecast an EPS of -0.22 USD, with revenue projected to reach -- USD, implying an نقصان of -72.15% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, GT Biopharma Inc. Common Stock reported EPS of -$0.79, missing estimates by -103.82%, and revenue of $0.00, 0% as expectations.
The stock price moved down -25.34%, changed from $0.92 before the earnings release to $0.69 the day after.
The next earning report is scheduled for ١٩ فبراير ٢٠٢٦.
Based on 3 المحللين, GT Biopharma Inc. Common Stock is expected to report EPS of -$0.22 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان